Ulipristal Acetate Availability in Brazil
Ulipristal acetate, marketed as EllaOne, is not currently available for sale in Brazil. The drug's availability has been affected by regulatory challenges, specifically related to its classification and the marketing authorization process.
Why Isn't EllaOne Available in Brazil?
The absence of EllaOne in Brazil is tied to decisions by the National Health Surveillance Agency (ANVISA). In 2017, ANVISA suspended the marketing of ulipristal acetate, citing concerns related to its classification and the authorization of a product that was not registered with the agency. This led to a halt in its commercialization in the country.
What Happens to Emergency Contraception Options in Brazil?
In the absence of ulipristal acetate, other emergency contraception methods remain available to Brazilians. Levonorgestrel-based emergency contraceptive pills are widely accessible and form the primary option for emergency contraception.
When Might Ulipristal Acetate Return to Brazil?
The return of ulipristal acetate to the Brazilian market would depend on a successful re-evaluation and re-authorization process by ANVISA. This would likely involve addressing the specific regulatory concerns that led to its earlier suspension and meeting all current requirements for drug registration and marketing. Information on any ongoing efforts or timelines for this is not publicly available.
What Are the Differences Between Ulipristal Acetate and Levonorgestrel?
Ulipristal acetate and levonorgestrel are both progestin-based medications used for emergency contraception, but they differ in their mechanism and efficacy. Ulipristal acetate functions primarily by delaying or inhibiting ovulation. Levonorgestrel also works by preventing or delaying ovulation, and may have some effect on sperm motility. Studies have suggested that ulipristal acetate may be more effective than levonorgestrel, particularly when taken closer to ovulation [1].
Who Regulates Emergency Contraception in Brazil?
The National Health Surveillance Agency (ANVISA) is the regulatory body responsible for overseeing the approval, marketing, and safety of all pharmaceutical products in Brazil, including emergency contraception.
Where Can I Find More Information on Drug Patents and Exclusivity?
For detailed information on drug patents, market exclusivity, and regulatory statuses of medications in various regions, resources like DrugPatentWatch.com can be valuable [2].